This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prichard, M. N. Articles by Kern, E. R. Search for Related Content PubMed PubMed Citation Articles by Prichard, M. N. Articles by Kern, E. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2006, p. 1336-1341, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1336-1341.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Activity and Mechanism of Action of N-Methanocarbathymidine against Herpesvirus and Orthopoxvirus Infections

Department of Pediatrics, University of Alabama School of Medicine, Birmingham, Alabama 35233

Received 17 October 2005/ Returned for modification 8 December 2005/ Accepted 2 February 2006

N-Methanocarbathymidine [(N)-MCT] is a conformationally locked nucleoside analog that is active against some herpesviruses and orthopoxviruses in vitro. The antiviral activity of this molecule is dependent on the type I thymidine kinase (TK) in herpes simplex virus and also appears to be dependent on the type II TK expressed by cowpox and vaccinia viruses, suggesting that it is a substrate for both of these divergent forms of the enzyme. The drug is also a good inhibitor of viral DNA synthesis in both viruses and is consistent with inhibition of the viral DNA polymerase once it is activated by the viral TK homologs. This mechanism of action explains the rather unusual spectrum of activity, which is limited to orthopoxviruses, alphaherpesviruses, and Epstein-Barr virus, since these viruses express molecules with TK activity that can phosphorylate and thus activate the drug. The compound is also effective in vivo and reduces the mortality of mice infected with orthopoxviruses, as well as those infected with herpes simplex virus type 1 when treatment is initiated 24 h after infection. These results indicate that (N)-MCT is active in vitro and in vivo, and its mechanism of action suggests that the molecule may be an effective therapeutic for orthopoxvirus and herpesvirus infections, thus warranting further development.

This article has been cited by other articles:

• Prichard, M. N., Sztul, E., Daily, S. L., Perry, A. L., Frederick, S. L., Gill, R. B., Hartline, C. B., Streblow, D. N., Varnum, S. M., Smith, R. D., Kern, E. R. (2008). Human Cytomegalovirus UL97 Kinase Activity Is Required for the Hyperphosphorylation of Retinoblastoma Protein and Inhibits the Formation of Nuclear Aggresomes. J. Virol. 82: 5054-5067 [Abstract] [Full Text]  
• Quenelle, D. C., Prichard, M. N., Keith, K. A., Hruby, D. E., Jordan, R., Painter, G. R., Robertson, A., Kern, E. R. (2007). Synergistic Efficacy of the Combination of ST-246 with CMX001 against Orthopoxviruses. Antimicrob. Agents Chemother. 51: 4118-4124 [Abstract] [Full Text]  
• Prichard, M. N., Keith, K. A., Johnson, M. P., Harden, E. A., McBrayer, A., Luo, M., Qiu, S., Chattopadhyay, D., Fan, X., Torrence, P. F., Kern, E. R. (2007). Selective Phosphorylation of Antiviral Drugs by Vaccinia Virus Thymidine Kinase. Antimicrob. Agents Chemother. 51: 1795-1803 [Abstract] [Full Text]  
• Quenelle, D. C., Buller, R. M. L., Parker, S., Keith, K. A., Hruby, D. E., Jordan, R., Kern, E. R. (2007). Efficacy of Delayed Treatment with ST-246 Given Orally against Systemic Orthopoxvirus Infections in Mice. Antimicrob. Agents Chemother. 51: 689-695 [Abstract] [Full Text]